{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:38:16Z","timestamp":1791981496747,"version":"4.4.0"},"reference-count":143,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriasis is a chronic systemic inflammatory disease causing erythematosus and scaly skin plaques; up to 30% of patients with psoriasis develop Psoriatic Arthritis (PsA), which is characterised by inflammation and progressive damage of the peripheral joints and\/or the spine and\/or the entheses. The pathogenic mechanisms driving the skin disorder in psoriasis and the joint disease in PsA are sustained by the activation of inflammatory pathways that can be overlapping, but also, at least partially, distinct. Cytokines members of the IL-23\/IL-17 family, critical in the development of autoimmunity, are abundantly expressed within the cutaneous lesions but also seem to be involved in chronic inflammation and damage of the synovium though, as it will be here discussed, not in all patients. In this review, we will focus on the state of the art of the molecular features of psoriatic skin and joints, focusing on the specific role of the IL-23\/IL-17 pathway in each of these anatomical districts. We will then offer an overview of the approved and in-development biologics targeting this axis, emphasising how the availability of the \u201ctarget\u201d in the diseased tissues could provide a plausible explanation for the heterogeneous clinical efficacy of these drugs, thus opening future perspective of personalised therapies.<\/jats:p>","DOI":"10.3390\/ijms19020530","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T12:46:27Z","timestamp":1518180387000},"page":"530","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":211,"title":["Role of the IL-23\/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1519-6902","authenticated-orcid":false,"given":"Marie-Astrid","family":"Boutet","sequence":"first","affiliation":[{"name":"Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute and Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Nerviani","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute and Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gallo Afflitto","sequence":"additional","affiliation":[{"name":"Unit of Allergology, Immunology & Rheumatology, Department of Medicine, Universit\u00e0 campus Bio-Medico di Roma, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Pitzalis","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute and Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The Epidemiology of Psoriatic Arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/ard.2008.094839","article-title":"Cardiovascular morbidity in psoriatic arthritis","volume":"68","author":"Gladman","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s10067-016-3396-5","article-title":"Malignancy incidence in patients with psoriatic arthritis: A comparison cohort-based incidence study","volume":"35","author":"Wilton","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_6","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Can. Fam. Phys. Med. Fam. Can."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jdv.12562","article-title":"Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review","volume":"28","author":"Rouzaud","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","first-page":"S26","article-title":"Peripheral joint involvement in psoriatic arthritis patients","volume":"33","author":"FitzGerald","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_11","first-page":"S31","article-title":"The involvement of the spine in psoriatic arthritis","volume":"33","author":"Baraliakos","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kim, T.-G., Kim, S., and Lee, M.-G. (2017). The Origin of Skin Dendritic Cell Network and Its Role in Psoriasis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010042"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.it.2005.10.003","article-title":"Understanding the IL-23\u2013IL-17 immune pathway","volume":"27","author":"McKenzie","year":"2006","journal-title":"Trends Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3899\/jrheum.090218","article-title":"Psoriatic arthritis sine psoriasis","volume":"83","author":"Olivieri","year":"2009","journal-title":"J. Rheumatol. Suppl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2017.04.005","article-title":"Lessons learned from twins in autoimmune and chronic inflammatory diseases","volume":"83","author":"Generali","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/BOR.0000000000000136","article-title":"What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?","volume":"27","author":"Eder","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s10096-014-2309-2","article-title":"The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infections","volume":"34","author":"Jaeger","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/jid.2010.214","article-title":"Carriers of Rare Missense Variants in IFIH1 Are Protected from Psoriasis","volume":"130","author":"Li","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/annrheumdis-2016-210592","article-title":"A rare coding allele in IFIH1 is protective for psoriatic arthritis","volume":"76","author":"Bowes","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1038\/ncomms7046","article-title":"Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s10067-017-3784-5","article-title":"Association of variably expressed KIR3dl1 alleles with psoriatic disease","volume":"36","author":"Berinstein","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1136\/annrheumdis-2014-207187","article-title":"PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: Evidence for a further PsA-specific risk locus","volume":"74","author":"Bowes","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/ced.13100","article-title":"HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment","volume":"42","author":"West","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jaad.2015.08.055","article-title":"HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up","volume":"74","author":"Talamonti","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/ard.2007.071399","article-title":"Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: Comparison with psoriasis and undifferentiated inflammatory arthritis","volume":"67","author":"Ho","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/annrheumdis-2017-211414","article-title":"Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis","volume":"76","author":"Bowes","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","first-page":"586","article-title":"HLA antigens in psoriatic arthritis","volume":"13","author":"Gladman","year":"1986","journal-title":"J. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PTT.S118348","article-title":"The metabolomics of psoriatic disease","volume":"7","author":"Yan","year":"2017","journal-title":"Psoriasis Targets Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1021\/pr500782g","article-title":"LC\u2013MS Metabolomics of Psoriasis Patients Reveals Disease Severity-Dependent Increases in Circulating Amino Acids That Are Ameliorated by Anti-TNF\u03b1 Treatment","volume":"14","author":"Kamleh","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.12688\/f1000research.9592.1","article-title":"Recent advances in understanding and managing psoriatic arthritis","volume":"5","author":"Gladman","year":"2016","journal-title":"F1000Research"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5114\/pdia.2014.40920","article-title":"Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: Atopic dermatitis, psoriasis and skin mastocytosis","volume":"2","author":"Nedoszytko","year":"2014","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/CCID.S124886","article-title":"Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis","volume":"10","author":"Carneiro","year":"2017","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e0004","DOI":"10.5041\/RMMJ.10279","article-title":"Comorbidities in Patients with Psoriatic Arthritis","volume":"8","author":"Haddad","year":"2017","journal-title":"Rambam Maimonides Med. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jdv.14286","article-title":"Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries","volume":"31","author":"Augustin","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Chau, T., Parsi, K.K., Ogawa, T., Kiuru, M., Konia, T., Li, C.-S., and Fung, M.A. (2017). Psoriasis or not? Review of 51 clinically confirmed cases reveals an expanded histopathologic spectrum of psoriasis. J. Cutan. Pathol.","DOI":"10.1111\/cup.13033"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"R569","DOI":"10.1186\/ar1698","article-title":"Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis","volume":"7","author":"Kruithof","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.autrev.2012.10.002","article-title":"Immunomodulation in psoriatic arthritis: Focus on cellular and molecular pathways","volume":"12","author":"Chimenti","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/ar1747","article-title":"Psoriatic arthritis synovial histopathology: Commentary on the article by Kruithof and colleagues","volume":"7","author":"Fitzgerald","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/BOR.0b013e32835fd8eb","article-title":"New learnings on the pathophysiology of RA from synovial biopsies","volume":"25","author":"Pitzalis","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/ard.2006.062042","article-title":"Ectopic lymphoid neogenesis in psoriatic arthritis","volume":"66","author":"Canete","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","unstructured":"(2017, September 01). Pathobiology of Early Arthritis Cohort (PEAC). Available online: http:\/\/www.peac-mrc.mds.qmul.ac.uk\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2016.07.003","article-title":"Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS)","volume":"239","author":"Sala","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semarthrit.2016.05.012","article-title":"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?","volume":"46","author":"Coates","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.12322","article-title":"Is chronic plaque psoriasis triggered by microbiota in the skin?","volume":"169","author":"Fry","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.autrev.2016.09.004","article-title":"Psoriasis and autoimmunity","volume":"15","author":"Sticherling","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1084\/jem.20101824","article-title":"Cutaneous immunosurveillance by self-renewing dermal \u03b3\u03b4 T cells","volume":"208","author":"Sumaria","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Nestle","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/ar2580","article-title":"Psoriatic arthritis: From pathogenesis to therapy","volume":"11","author":"FitzGerald","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0198-8859(99)00034-8","article-title":"Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis","volume":"60","author":"Tassiulas","year":"1999","journal-title":"Hum. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780390118","article-title":"Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis","volume":"39","author":"Pitzalis","year":"1996","journal-title":"Arthritis Rheum."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Dolcino, M., Lunardi, C., Ottria, A., Tinazzi, E., Patuzzo, G., and Puccetti, A. (2014). Crossreactive Autoantibodies Directed against Cutaneous and Joint Antigens Are Present in Psoriatic Arthritis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115424"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.4049\/jimmunol.166.4.2878","article-title":"Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven","volume":"166","author":"Costello","year":"2001","journal-title":"J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nri3700","article-title":"Ectopic lymphoid-like structures in infection, cancer and autoimmunity","volume":"14","author":"Pitzalis","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Humby, F., Bombardieri, M., Manzo, A., Kelly, S., Blades, M.C., Kirkham, B., Spencer, J., and Pitzalis, C. (2009). Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.0060001"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/jid.2013.534","article-title":"Dermal Clusters of Mature Dendritic Cells and T Cells Are Associated with the CCL20\/CCR6 Chemokine System in Chronic Psoriasis","volume":"134","author":"Kim","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/cei.12376","article-title":"Interleukin (IL)-17A, F and AF in inflammation: A study in collagen-induced arthritis and rheumatoid arthritis: IL-17 subtypes in inflammatory arthritis","volume":"177","author":"Sarkar","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4049\/jimmunol.177.1.36","article-title":"Cutting Edge: Interleukin 17 Signals through a Heteromeric Receptor Complex","volume":"177","author":"Toy","year":"2006","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23\u2013IL-17 immune axis: From mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/imr.12027","article-title":"IL-22, not simply a Th17 cytokine","volume":"252","author":"Rutz","year":"2013","journal-title":"Immunol. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Eyerich, S., Eyerich, K., Pennino, D., Carbone, T., Nasorri, F., Pallotta, S., Cianfarani, F., Odorisio, T., Traidl-Hoffmann, C., and Behrendt, H. (2009). Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Investig.","DOI":"10.1172\/JCI40202"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: As a drug target for autoimmune inflammatory diseases: IL-23 in autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23-IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nature07036","article-title":"Induction and effector functions of TH17 cells","volume":"453","author":"Bettelli","year":"2008","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cellimm.2015.01.011","article-title":"Dermal \u03b3\u03b4 T cells\u2014What have we learned?","volume":"296","author":"Born","year":"2015","journal-title":"Cell. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11596-007-0329-1","article-title":"Expression of Th17 cytokines in skin lesions of patients with psoriasis","volume":"27","author":"Li","year":"2007","journal-title":"J. Huazhong Univ. Sci. Technol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2007.082081","article-title":"Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: Differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis","volume":"68","author":"Brentano","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/art.20965","article-title":"Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine","volume":"52","author":"Ikeuchi","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Van Baarsen, L.G., Lebre, M.C., van der Coelen, D., Aarrass, S., Tang, M.W., Ramwadhdoebe, T.H., Gerlag, D.M., and Tak, P.P. (2014). Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: Possible explanation for nonresponse to anti-IL-17 therapy?. Arthritis Res. Ther., 16.","DOI":"10.1186\/s13075-014-0426-z"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2\u2013dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/eji.200535503","article-title":"IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: A potential role in psoriasis","volume":"36","author":"Wolk","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ma, H.-L., Liang, S., Li, J., Napierata, L., Brown, T., Benoit, S., Senices, M., Gill, D., Dunussi-Joannopoulos, K., and Collins, M. (2008). IL-22 is required for Th17 cell\u2013mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Investig.","DOI":"10.1172\/JCI33263"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.imlet.2009.10.012","article-title":"IL-23 induces receptor activator of NF-\u03baB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-\u03baB signal pathways","volume":"127","author":"Li","year":"2010","journal-title":"Immunol. Lett."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Ca\u00f1ete, J.D., Celis, R., Yeremenko, N., Sanmart\u00ed, R., van Duivenvoorde, L., Ram\u00edrez, J., Blijdorp, I., Garc\u00eda-Herrero, C.M., Pablos, J.L., and Baeten, D.L. (2015). Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis. Arthritis Res. Ther., 17.","DOI":"10.1186\/s13075-015-0688-0"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","article-title":"Incomplete response of inflammatory arthritis to TNF\u03b1 blockade is associated with the Th17 pathway","volume":"71","author":"Alzabin","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative Genomic Profiling of Synovium Versus Skin Lesions in Psoriatic Arthritis: Genomic Profiling of Psoriatic Arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/ar3817","article-title":"Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features","volume":"14","author":"Celis","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10067-016-3500-x","article-title":"Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints","volume":"36","author":"Fiocco","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4\u2212CD8\u2212 entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar3781","article-title":"Functional role of IL-22 in psoriatic arthritis","volume":"14","author":"Mitra","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Eberle, F.C., Br\u00fcck, J., Holstein, J., Hirahara, K., and Ghoreschi, K. (2016). Recent advances in understanding psoriasis. F1000Research, 5.","DOI":"10.12688\/f1000research.7927.1"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A Human Interleukin-12\/23 Monoclonal Antibody for the Treatment of Psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and Efficacy of ABT-874, a Fully Human Interleukin 12\/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis: Results of a Randomized, Placebo-Controlled, Phase 2 Trial","volume":"144","author":"Kimball","year":"2008","journal-title":"Arch. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-Week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-Week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: Results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up: Long-term ustekinumab safety in psoriasis","volume":"168","author":"Papp","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: Results from the PHOENIX 1 trial through up to 3 years: Long-term efficacy of ustekinumab in moderate-to-severe psoriasis","volume":"166","author":"Kimball","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjd.12632","article-title":"Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: Results from PHOENIX 1","volume":"170","author":"Rich","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: Post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","article-title":"Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2133.2011.10418.x","article-title":"Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Gottlieb","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","article-title":"A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis","volume":"365","author":"Reich","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/j.1468-3083.2012.04705.x","article-title":"Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12\/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis: Pooled safety analysis of briakinumab in psoriasis","volume":"27","author":"Langley","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40265-017-0800-7","article-title":"Guselkumab: First Global Approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23\u2013specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Langley, R.G., Tsai, T.-F., Flavin, S., Song, M., Randazzo, B., Wasfi, Y., Jiang, J., Li, S., and Puig, L. (2017). Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, phase III NAVIGATE trial. Br. J. Dermatol.","DOI":"10.1111\/bjd.16175"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","article-title":"Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody","volume":"7","author":"Singh","year":"2015","journal-title":"mAbs"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis\u2014Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/ijd.13236","article-title":"Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: Results of two phase 3, randomized, placebo-controlled clinical trials","volume":"55","author":"Strober","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","article-title":"Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: Results from a randomised phase III trial (FUTURE 1)","volume":"76","author":"Strand","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study: PsA and Long-Term Treatment With Secukinumab","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.39685","article-title":"Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","article-title":"Secukinumab: First Global Approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jaad.2016.07.034","article-title":"Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials","volume":"75","author":"Kimball","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.2174\/1381612821666150310145758","article-title":"Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: Role of synovial pathobiology","volume":"21","author":"Astorri","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.2011.10419.x","article-title":"Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Strober","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.4049\/jimmunol.1302190","article-title":"Pharmacologic Inhibition of ROR t Regulates Th17 Signature Gene Expression and Suppresses Cutaneous Inflammation In Vivo","volume":"192","author":"Skepner","year":"2014","journal-title":"J. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.intimp.2014.04.018","article-title":"Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model","volume":"21","author":"Li","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.4049\/jimmunol.1300047","article-title":"IL-37 Ameliorates the Inflammatory Process in Psoriasis by Suppressing Proinflammatory Cytokine Production","volume":"192","author":"Teng","year":"2014","journal-title":"J. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Boutet, M.-A., Najm, A., Bart, G., Brion, R., Touchais, S., Trichet, V., Layrolle, P., Gabay, C., Palmer, G., and Blanchard, F. (2017). IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro. Ann. Rheum. Dis.","DOI":"10.1136\/annrheumdis-2017-eular.2257"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/rheumatology\/kew325","article-title":"Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation","volume":"55","author":"Cavalli","year":"2016","journal-title":"Rheumatology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.4049\/jimmunol.1401810","article-title":"IL-37 Alleviates Rheumatoid Arthritis by Suppressing IL-17 and IL-17-Triggering Cytokine Production and Limiting Th17 Cell Proliferation","volume":"194","author":"Ye","year":"2015","journal-title":"J. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni.3103","article-title":"IL-37 requires the receptors IL-18R\u03b1 and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction","volume":"16","author":"Lo","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1073\/pnas.1121534109","article-title":"IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist","volume":"109","author":"Stoeckman","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/2\/530\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:54:29Z","timestamp":1760194469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/2\/530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":143,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2]]}},"alternative-id":["ijms19020530"],"URL":"https:\/\/doi.org\/10.3390\/ijms19020530","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]}}}